-
SABCS 2024 | Dr. Wenbin Zhou: Efficacy of Pyrotinib-Based Regimen in Neoadjuvant Therapy for HER2-Enriched Breast Cancer
Breast cancer remains a leading malignancy threatening women’s health, and optimizing treatment strategies continues to be a major focus of research. Neoadjuvant therapy, especially for HER2-positive breast cancer, plays a key role in improving survival outcomes and quality of life. The 47th San Antonio Breast Cancer Symposium (SABCS) will take place from December 10 to…
-
SABCS 2024 | Dr. Huiping Li & Dr. Hanfang Jiang: Hetrombopag – A New Option for CTIT Treatment in Breast Cancer Patients?
The 47th San Antonio Breast Cancer Symposium (SABCS) will be held from December 10 to 13, 2024, in San Antonio, USA. A phase II prospective study led by Professors Huiping Li and Hanfang Jiang from Peking University Cancer Hospital will be presented as a poster (Abstract No: P1-02-12). This study explores the efficacy and safety…
-
SABCS 2024 | Dr. Hui Xie: Exploring the Degradomic Features of Mammary Tumor-Adjacent Adipocytes and MASP6 as a Potential Therapeutic Target
The 47th San Antonio Breast Cancer Symposium (SABCS) will be held from December 10 to 13, 2024, in San Antonio, Texas, USA. As the largest and most influential breast cancer-focused academic meeting globally, the conference will unveil a series of groundbreaking research findings. A study conducted by Dr. Hui Xie and her team from The…
-
CACA-GO | Professor Declan Murphy on Whether Pelvic Lymph Node Dissection for Prostate Cancer Is “Dead”
The 14th Shanghai Genitourinary Oncology Academic Conference and Annual Meeting of Chinese Anti-Cancer Association—Genitourinary Oncology Committee (CACA-GO) recently took place in Shanghai. The conference invited numerous internationally renowned experts in uro-oncology to deliver academic presentations and perform surgical demonstrations. Professor Declan Murphy from the Peter MacCallum Cancer Centre in Australia delivered a compelling talk titled…
-
AASLD 2024: Dr. Mingqin Lu’s Team Presents Study on Biomimetic Exosomes Loaded with Iridium Nanozyme for Acute Liver Failure Treatment
Acute liver failure (ALF) is a severe clinical syndrome characterized by the rapid deterioration of liver function, often accompanied by multi-organ failure. Given its complex mechanisms and limited treatment options,…
-
ESMO Asia 2024 | Professor Ming Cao on Bladder-Sparing Strategies Combining Local Surgery and Chemoradiotherapy for MIBC Patients
Radical cystectomy remains the standard treatment for muscle-invasive bladder cancer (MIBC), but many patients express a strong desire to preserve their bladder. To address this, various bladder-sparing strategies have been explored, including transurethral resection of bladder tumor (TURBT), partial cystectomy (PC), chemotherapy, radiotherapy, and surveillance. At the recent ESMO Asia Annual Meeting, Professor Ming Cao…
-
ESMO Asia 2024 | Professor Xuefeng Qiu Reviews Progress in Prostate Cancer Diagnosis and Treatment, Shares Research Achievements from Gulou Hospital
As 2024 draws to a close, the field of oncology celebrates the year’s grand finale with the ESMO ASIA Annual Meeting. The conference not only attracted top scholars and researchers from across Asia and the global oncology community but also showcased numerous breakthroughs in urologic oncology. On-site at the conference, Urology Frontier invited Professor Xuefeng…
-
ESMO Asia 2024 | Early Trials Show Favorable Benefit-Risk Profiles for Oral Small-Molecule PD-L1 Inhibitor
At the 2024 ESMO Asia Congress “Preferred Oral Presentations – Development and Precision Medicine” session, two oral immune checkpoint inhibitors (ICIs) for solid tumors demonstrated initial efficacy and manageable safety in early-phase trials. These results support further development of novel small-molecule PD-L1 inhibitors, which offer favorable benefit-risk profiles and better usability compared to antibody-based ICIs.
Connecting Medical Expertise through Media